Grifols SA PT receives Investment Bank Analyst Rating Update
Investing.com - Grifols ADR reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Grifols ADR announced earnings...
Kepler Capital analyst Arnaud Girod maintained a Hold rating on Grifols SA (NASDAQ:GRFS) on Wednesday, setting a price target of EUR22.9, which is approximately 141.03% above...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced that the first patient has begun treatment in the third and final cohort of an investigator-led phase I study, evaluating a...
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
|Average||13.30 (+92.47% Upside)|
|No. of Analysts||2|